Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease. Samples will come from patients suffering from different diseases for which Janssen is developing drugs, including but not limited to rheumatoid arthritis, inflammatory bowel disease, lupus, and cardiovascular and metabolic conditions.
 
“We are happy that the Janssen research teams are exploring the potential of our protein-measurement platform for their drug discovery and development efforts,” said Roy Smythe, SomaLogic chief executive officer. “We prefer this kind of ‘win-win’ collaboration, where each party shares data and expertise with the other in an effort to achieve the high value goal of more rapidly advancing healthcare.”